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Abstract 
Aging leads to increased cellular senescence and is associated with decreased potency of 
tissue-specific stem/progenitor cells. Here we have done an extensive analysis of cardiac 
progenitor cells (CPCs) isolated from human subjects with cardiovascular disease (n=119), 
aged 32-86 years.  In aged subjects (>74 years old) over half of CPCs are senescent 
(p16
INK4A
, SA-β-gal, DNA damage γH2AX, telomere length, Senescence-Associated 
Secretory Phenotype (SASP)), unable to replicate, differentiate, regenerate or restore cardiac 
function following transplantation into the infarcted heart. SASP factors secreted by 
senescent CPCs renders otherwise healthy CPCs to senescence. Elimination of senescent 
CPCs using senolytics abrogates the SASP and its debilitative effect in vitro. Global 
elimination of senescent cells in aged mice (INK-ATTAC or wildtype mice treated with D+Q 
senolytics) in vivo activates resident CPCs (0.23±0.06% vs. 0.01±0.01% vehicle; p<0.05) and 
increased the number of small, proliferating Ki67-, EdU-positive cardiomyocytes 
(0.25±0.07% vs. 0.03±0.03% vehicle; p<0.05). Therapeutic approaches that eliminate 
senescent cells may alleviate cardiac deterioration with aging and rejuvenate restore the 
regenerative capacity of the heart. 
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Introduction 
Ageing is the greatest risk factor for many life-threatening disorders, including cardiovascular 
diseases, neurodegenerative diseases, cancer, and metabolic syndromes (St Sauver et al. 
2015). Aging leads to increased cellular senescence in a number of tissues and is frequently 
associated with increased expression of the senescence biomarker, p16
Ink4a
 (also known as 
Cdkn2a), resistance to apoptosis, and impaired proliferation and tissue regeneration 
(Jeyapalan and Sedivy, 2008; Sharpless and DePinho, 2007; Krishnamurthy et al. 2004). 
Senescent cells disrupt tissue structure and function through their senescence-associated 
secretory phenotype (SASP), consisting of pro-inflammatory cytokines, chemokines, and 
ECM-degrading proteins, and other factors, which have deleterious paracrine and systemic 
effects (Tchkonia et al. 2013; Xu et al. 2015, eLIFE; Xu et al. 2015, PNAS). Remarkably, 
even a relatively low abundance of senescent cells (10-15% in aged primates) is sufficient to 
cause tissue dysfunction (Herbig et al. 2006).   
 
To test whether senescent cells are causally implicated in age-related dysfunction and 
whether their removal is beneficial, J. L. Kirkland, T. Tchkonia, D. Baker (Mayo), J. van 
Deursen (Mayo), D. Baker (Mayo) and colleagues made use of a promoter for the biomarker 
for senescence, p16
INK4a
, and an inducible “suicide” gene designed by P. Scherer et al. 
(Pajvani et al. 2005) to develop a novel transgene, INK-ATTAC, to permit inducible 
elimination of p16
INK4a
-positive senescent cells upon administration of a drug (AP20187) 
(Baker et al. 2011). In these mice, eliminating a relatively small proportion (~30%) of 
senescent cells extends health span and prevents the development of multiple age-related 
morbidities in both progeroid and normal, chronologically aged mice (Baker et al. 2011; 
Roos et al. 2016; Farr et al. 2017; Ogrodnik et al. 2017; Schafer et al. 2017; Xu et al. 2018). 
Moreover, late life clearance attenuated the progression of already established age-related 
disorders (Xu et al. 2018). To be applicable to humans, Kirkland and collaborators have 
identified a new class of drugs named senolytics in work that paralleled, but was not 
dependent on development of INK-ATTAC mice. Through exploiting senescent cells’ 
dependence on specific pro-survival pathways, senolytics specifically kill senescent cells 
without affecting proliferating or quiescent, differentiated cells (Kirkland and Tchkonia, 
2015; Kirkland et al. 2017; Kirkland and Tchkonia, 2017). Recent studies have documented 
senolytic drugs for the selective clearance of senescent cells from ‘aged’ tissues, which led to 
delayed acquisition of age-related pathologies (Tchkonia and Kirkland, 2018). Recently, the 
Kirkland lab has demonstrated that transplanting relatively small numbers of senescent 
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preadipocyte cells into young (6 month old) mice causes persistent physical dysfunction, 
measured through maximal speed, hanging endurance and grip strength, 1 month after 
transplantation. Transplanting even fewer senescent cells into older (17 month old) recipients 
had the same effect and reduced survival, indicating the potency of senescent cells in 
shortening health- and lifespan. Intermittent oral administration of the senolytics, dasatinib 
(D), a FDA-approved tyrosine kinase inhibitor, and quercetin (Q), a flavonoid present in 
many fruits and vegetables, to senescent cell-transplanted young mice and naturally aged 
mice alleviated physical dysfunction and increased post-treatment survival by 36% while 
reducing mortality hazard to 65% (Xu et al. 2018). Altogether these data indicate that cellular 
senescence is causally implicated in generating age-related phenotypes and that systemic 
removal of senescent cells can prevent or delay tissue dysfunction, physical dysfunction and 
extend health- and lifespan. 
 
Like other organs, the adult mammalian heart has the capacity, albeit low, to self-renew 
cardiomyocytes over the human lifespan (Bergmann et al. 2009), and genetic fate mapping 
models show that one source of new cardiomyocytes are a population of resident stem cells 
(Ellison et al. 2013; Hsieh et al. 2007). Multiple labs have shown the mammalian heart, 
including human, to harbour self-renewing, clonogenic, multipotent cardiac stem and 
progenitor cells (CSCs or CPCs; abbreviated hereafter as CPCs) with regenerative potential 
in vivo (Ellison-Hughes and Lewis, 2017; Vicinanza et al. 2017). An undisputed mechanism 
of action of CPC transplantation into the infarcted myocardium is their secretome reparative 
potential, which through acting in a paracrine manner improves cardiomyocyte survival, 
limits fibrosis, induces angiogenesis, new cardiomyocyte formation and restores cardiac 
function (Broughton et al. 2018) .  
 
Our lab has defined the CPC population to be Sca-1
pos
/c-kit
pos
/CD31
neg
/CD45
 neg
/Tryptase
 neg
 
(Ellison et al. 2013; Vicinanza et al. 2017; Ellison et al. 2011) distinguishing them from 
cardiac c-kit
pos 
endothelial (CD31
pos
) and mast (CD45
pos
/Tryptase
pos
) cells. The CPCs are a 
rare population in the adult heart, with ~1% evidencing cardiomyogenic regeneration 
potential (Vicinanza et al. 2017). Recently, considerable confusion has emanated over the 
significant cardiomyogenic potential of CPCs purported using Kitcre Knockin or dual 
recombinases-mediated cell tracking mouseice models (van Berlo et al. 2014; Sultana et al. 
2015; Li et al. 2018). However, these models do not tag or specifically lineage trace the 
CPCs, neither have the investigators isolated, characterised or transplanted CPCs (according 
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to the Sca-1
pos
/c-kit
pos
/CD31
neg
/CD45
 neg
/Tryptase
 neg
 phenotype given above) from these 
mice to test their stem cell and regenerative properties. Moreover, the c-kitCre null allele 
produced by Cre insertion fails to recombine the CPCs in the Kitcre mice and there  is a 
severe defect in CPC myogenesis produced by the c-kit hemizygosity (Vicinanza et al. 2018).  
 
Cardiac aging and pathology affects the activity and potency CPCs (Cesselli et al. 2011; 
Castaldi et al. 2017; Torella et al. 2004), which translates into a diminished capacity of the 
aged and diseased myocardium to maintain homeostasis, and repair and regenerate following 
injury (Ellison and Lewis et al. 20174). The aging milieu might therefore limit the success of 
cell transplantation therapies where the outcome is direct cardiogenic differentiation of 
transplanted cells and/or stimulation of endogenous regenerative mechanisms. As the 
majority of cardiovascular disease patients in need of regenerative therapies are of advanced 
age, regulation of CPC and cardiovascular aging/senescence is mission critical.  
 
Here we have carried out an extensive analysis of CPCs in the human failing heart with 
advanced age and show the accumulation of senescent-CPCs, which exhibit diminished self-
renewal, differentiation, and regenerative potential in vivo. We show that Senescent-CPCs 
have a SASP that negatively affects healthy non-senescent, cycling-competent CPCs, 
rendering them senescent. Clearing the senescent-CPCs using senolytics attenuates the SASP 
and its effect on promoting senescence in vitro. The effects of global elimination of senescent 
cells on the heart and its regenerative capacity have not been elucidated. We report novel data 
that show systemic elimination of senescent cells in vivo in aged mice using senolytics (D+Q) 
or using the ‘suicide’ transgene, INK-ATTAC with administration of AP20187, results in 
CPC activation and increased number of small, immature, proliferating EdU+ 
cardiomyocytes in the aged mouse heart.  
 
Results 
CPCs exhibit a senescent phenotype with increased age 
Human CPCs were isolated from biopsies of right atria, obtained from subjects who had 
given informed consent before undergoing cardiac surgery (aortic disease, valve disease, 
coronary artery bypass graft (CABG), or multiple diseases), using sequential enzymatic 
digestion and dissociation, Optiprep density gradient to remove large debris, followed by 
magnetic activated cell sorting (MACS) (Supplementary Figure 1a). CPCs were 
magnetically enriched based upon a CD45-negative, CD31-negative, CD34-negative, and c-
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kit-positive sorting strategy (Smith et al. 2014; Vicinanza et al. 2017) (Supplementary 
Figure 1b). Despite being recognised as a CPC marker, cells were not sorted for Sca-1 
because its homology has not been confirmed in any species other than mouse. By flow 
cytometry analysis, CPCs showed expression of other recognised CPC markers such as CD90 
(37±0.4%), CD166 (41±1%), CD105 (13±1%), and CD140α (5±0.4%) (Supplementary 
Figure 1c). There were no differences in number of CPCs isolated from old (>70 years) 
subjects, compared to subjects <70 years. We also found no differences in number of CPCs 
isolated from male or female, or from those subjects with valve disease, coronary disease or 
aortic disease (Supplementary Figure 1d). 
 
We isolated CPCs from 35 subjects of different genders, ages, and pathologies and found a 
linear increase (R
2
=0.722) in the number of freshly isolated CPCs that expressed the 
senescence-associated marker, p16
INK4A
, with age (Figure 1a). Although a trend was evident, 
nNo differences were evident between males and females for p16
INK4A
 expression or between 
aortic disease, valvular disease, coronary artery disease, and multiple other diseases for 
p16
INK4A
 expression (Supplementary Figure 2a,b). Moreover, we found no differences 
between smokers (including ex-smokers) and non-smokers, diabetics and non-diabetics, and 
hypertensive and non-hypertensive subjects for p16
INK4A
-expressing CPCs (Supplementary 
Figure 2c-e). On average, 22±9%, 31±4%, 48±9%, and 56±16% of freshly isolated CPCs 
expressed p16
INK4Ank4a
 isolated from 50-59, 60-69, 70-79, and 80-89 year old subjects, 
respectively (Figure 1a). We also found an increase (P<0.05) in the number of senescence-
associated β-galactosidase- (SA-β-gal; ~60%) and DNA damage marker, γH2AX-positive 
CPCs (~20%) freshly isolated from old (71-79 years), compared to middle-aged (54-63 
years) subjects (Figure 1b,c). Moreover, p16
INK4A
-positive CPCs co-expressed γH2AX 
(Figure 1c). Further interrogation by Q-FISH revealed that, while the average telomere 
length of CPCs freshly isolated from old and middle-aged subjects’ hearts were comparable, 
CPCs freshly isolated from old (78-84 years) subjects’ hearts contained a 12% subpopulation 
with telomere length of <6Kb, which is regarded as being critically short (Figure 1d) (Canela 
et al. 2007). Approximately 2% of the CPCs freshly isolated from human hearts were Ki67-
positive, reflective of their mainly dormant, quiescent phenotype (Ellison et al. 2013). There 
were no differences between middle-aged and old subjects in number of Ki67-positive CPCs, 
and we did not see any Ki67-positive CPCs that were p16
INK4A
-positive (Supplementary 
Figure 2fc). These findings indicate that the aged human heart contains an increased 
proportion of aged senescent-CPCs, which could translate to their dysfunctionality. 
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CPCs from old subjects show impaired cell growth and differentiation 
CPCs were isolated from 5 old (76-86 years) and 8 middle-aged (32-66 years) subjects, 
plated in growth medium, and propagated, where possible, to passage 11. CPCs isolated from 
2 of the middle-aged (32 and 61 years) and 3 2 of the oldest (78 and, 80, and 86 years) 
subjects failed to grow and become established in vitro. . Of the CPC cultures that did grow 
from all age groups (n=8), the CPCs, from P3 to P11, gradually lost their p16
INK4A–positive 
subpopulation (Supplementary Figure 2gd,e), likely due to the cell culture activated, 
cycling-competent CPCs outgrowing their p16
INK4A–positive senescent counterparts. CPCs 
maintained the phenotype of c-kit-positive, CD31-negative over culture passage 
(Supplementary Figure 2hf). To ensure that the effect of donor age could be effectively 
evaluated, all in vitro cell dynamic assays were performed between P2-P4. 
 
CPCs isolated from old (77-86 years) subjects showed decreased (P<0.05) proliferation 
compared to CPCs isolated from middle-aged (34-62 years) subjects (Figure 2a). CPCs 
deposited as a single-cell in a 96-well plate generated a greater number (P<0.05) of clones if 
the single CPCs originated from middle-aged (34-62 years) subjects, compared to old (76-86 
years) subjects (Figure 2b). Likewise, CPCs deposited at low dilution in bacteriological 
dishes for the generation of spheres in suspension were greater in number and size (P<0.05) 
for middle-aged (34-51 years) subject’s’ CPCs, compared to old (76-77 years) subject’s’ 
CPCs (Figure 2c,d). When CPCs were plated in cardiomyocyte differentiation medium, they 
primed towards a cardiomyocyte-like precursor cell type that was Nkx2.5-positive, 
sarcomeric actin-positive, and mMiddle-aged (47-62 years) subject’s CPCs had increased 
(P<0.05) differentiation potential, compared to CPCs from old (76-77 years) subjects (Figure 
2e-g). Older subject’s differentiated CPC-derived precursor cells showed disorganised 
sarcomeric structure (Figure 2e) and decreased (P<0.05) expression (Figure 2g), compared 
to differentiated CPCs from younger, middle-aged subjects. 
 
Even though CPCs isolated from old hearts showed decreased proliferation, clonogenicity, 
and differentiation potential, only ~50% of CPCs are senescent in old myocardium (Figure 
1a), therefore these data imply that a functionally cycling-competent CPC population still 
exists in old myocardium. Indeed, single CPC-derived clones from younger young, middle-
aged, and old subjects were indistinguishable in terms of morphology, senescence, 
multipotency, self-renewing transcript profile, and differentiation (Supplementary Figure 
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3). These findings suggest that CPCs age and become senescent in a stochastic, non-
autonomous manner. This resembles what was seen in rat preadipocytes (Kirkland et al. 
1990). 
 
Aged-senescent CPCs lose their regenerative capacity in vivo 
To purify for a senescent population of CPCs we utilised the C12-5-
Dodecanoylaminofluorescein Di-β-D-Galactopyranoside (C12FDG) probe and pulled out 
SA-β-gal-positive CPCs through FACS (Supplementary Figure 4a-d). We also induced 
senescence in CPCs pharmacologically using Doxorubicin and Rosiglitazone 
(Supplementary Figure 4e-g), which we have used previously to render cells to senescence 
in vitro
 
(Xu et al. 2015 eLIFE; Xu et al. 2018). Senescent-CPCs, whether Doxorubicin-, or 
Rosiglitazone-induced or purified using the C12FDG probe, exhibited a senescent phenotype 
being p16
INK4A–positive, Ki67-negative, and with shorter telomeres (Supplementary Figure 
5). Senescent SA-β-gal-positive CPCs were non-proliferative and did not form clonal 
colonies when deposited as single cells, or generate spheres in vitro, compared to SA-β-gal-
negative, Ki67-positive cycling-competent CPCs (Supplementary Figure 5). FACS 
phenotyping revealed decreased surface expression of the progenitor markers, c-kit, CD90, 
CD105, and CD166 and increased expression of CD31 and CD34 in SA-β-gal-positive, 
senescent-CPCs compared to SA-β-gal-negative, cycling-competent CPCs (Supplementary 
Figure 6). 
 
To determine whether the dysfunctional stem/progenitor cell properties of the senescent-
CPCs translated in vivo, we tested the regenerative capacity of doxorubicin-induced senescent 
SA-β-gal-positive CPCs and cycling-competent SA-β-gal-negative CPCs in the myocardial 
infarction-regeneration mouse model (Figure 3a). To separate the impact of senescence from 
other potentially confounding aging processes operative in older mice, such as NAD 
deficiency, accumulation of advanced glycation end products, or accumulation of misfolded 
proteins, we transplanted senescent or and cycling-competent CPCs into young mice. Male, 
immunodeficient NSG mice were subjected to permanent ligation of the left anterior 
descending (LAD) coronary artery. Immediately after ligation, 5 x 10
5
 SA-β-gal-positive 
senescent or SA-β-gal-negative cycling-competent CPCs were injected intramyocardially in 
15µl of PBS at 2 sites in the border zone. To serve as a cell control, a separate set of MI-mice 
were injected with 5 x 10
5
 non-CPCs (c-kit
neg
 cardiac-derived cells; containing 86±5% 
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cardiac fibroblasts, 13±3% vascular smooth muscle, 1±1% endothelial cells (Ellison et al. 
2013)). Sham animals were treated the same way, except ligation of LAD coronary artery 
was not performed and they did not receive cells but were injected with the same volume of 
PBS. Mice were administered BrdU via osmotic mini pumps for 14 days after MI and cell 
injection to track new cell DNA formation (Figure 3a). All cell populations were labelled 
prior to injection with PKH26 lipophilic membrane dye, which exhibited high labelling 
efficiency and label dye retention over population doublings in cycling-competent CPCs and 
c-kit
neg
 cardiac-derived cells in vitro (Supplementary Figure 7). We sacrificed a sub-set of 
MI-mice that had been injected with 5 x 10
5
 SA-β-gal-negative cycling-competent CPCs at 4 
days. There was high engraftment and survival of CPCs within the infarct/border zone at 4 
days (Figure 3b) and by 28 days the engraftment was still ~10% of cycling-competent CPCs 
per total nuclei in the infarct/border zone (Figure 3c). The engraftment and survival of 
senescent-CPCs and c-kit
neg
 cells at 28 days was significantly (P<0.05) less (Figure 3c). 
 
At 1 week after LAD ligation all groups had decreased (P<0.05) LV function, compared to 
baseline and sham controls, however the group that had been injected with cycling-competent 
CPCs had less of a decrease in LV function at 1 week, compared to the senescent-CPC and 
non-CPC c-kit
neg
 cell groups (Figure 3d). The degree of MI represented as the % Average 
Area at Risk (AAR) through Evans Blue staining immediately after MI was 33.0±1.6% (n=5), 
demonstrating the operator as being extremely consistent in inducing a similar size MI injury 
to each mouse. At 4 weeks after LAD ligation, MI hearts that had received cycling-competent 
CPCs showed an improvement (P<0.05) in LV ejection fraction (EF), fractional shortening 
(FS), LVEDD, and LVESD, which had almost returned to baseline values and to that of 
Sham controls (Figure 3d).  
 
This extent of LV improvement was not apparent in MI-mice that were injected with SA-β-
gal-positive senescent-CPCs, or the non-CPC c-kit
neg
 cell group that showed no recovery with 
worsened LV function and were all in heart failure at 4 weeks (Figure 3d). To accompany 
these functional changes, cycling-competent CPC injection resulted in a decreased (P<0.05) 
infarct size, whereas SA-β-gal-positive senescent-CPCs or non-CPC c-kitneg cells did not 
change the extent of infarct size (Figure 3e). Immunohistochemical analysis of cross-sections 
revealed that at 4 weeks after MI, the transplanted PKH26-labelled cycling-competent CPCs 
had increased expression of sarcomeric proteins, α-actinin, as well as the endothelial lineage 
marker vWF, evidencing their differentiation into cardiomyocyte-like precursor cells and 
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endothelial cells, respectively (Figure 3f; Supplementary Figure 8a,b). Limited or no 
differentiation was evident in the infarcted/border zone of the hearts injected with PKH26-
labelled senescent-CPCs and non-CPC c-kit
neg
 cells (Figure 3f). To determine whether the 
transplanted cells had participated in inducing a paracrine effect, the infarct/border zone of 
hearts that had received cells were analysed for formation of new cells that were BrdU-
positive/PKH26-negative. Hearts that were injected with cycling-competent CPCs showed an 
increased number of BrdU-positive cells, compared to those injected with SA-β-gal-positive 
senescent-CPCs or non-CPC c-kit
neg
 cells (Supplementary Figure 8c,d). Moreover, these 
BrdU-positive cells co-localised with vWF or α-sarcomeric actinin, indicating new that these 
endothelial (capillary) cells and cardiomyocytes had been prompted to initiate DNA synthesis 
and suggest they may have entered the cell cycleformation, respectively. New BrdU-positive 
cardiomyocyte and capillariesry formation  wereas more evident (P<0.05) in the MI-cycling-
competent CPC group (Figure 3g). These findings show the diminished regenerative and 
reparative capacity of senescent CPCs, compared to healthy, cycling-competent CPCs.  
 
Aged-Senescent CPCs have a Senescence-Associated Secretory Phenotype (SASP) 
Senescent cells exhibit a SASP (Tchkonia et al. 2013). Senescent SA-β-gal-positive CPCs 
showed increased expression of SASP factors, including MMP-3, PAI1, IL-6, IL-8, IL-1β, 
and GM-CSF, compared to non-senescent, SA-β-gal-negative, cycling-competent CPCs 
(Figure 4a). To determine whether the SASP factors were secreted from senescent-CPCs, we 
quantified the protein levels of seven of the highly expressed SASP factors in conditioned 
media from senescent-CPCs using Luminex technology. We found increased (P<0.05) 
quantities of all seven SASP factors in senescent-CPC conditioned medium, compared to 
conditioned medium of cycling-competent CPCs (Figure 4b). Next we treated cycling-
competent CPCs with conditioned medium from senescent-CPCs and measured cell 
proliferation and senescence of the cycling-competent CPCs. Conditioned medium from 
senescent-CPCs resulted in decreased (P<0.05) proliferation (Figure 4c) and an increased 
(P<0.05) proportion of senescent p16
INK4A–positive, SA-β-gal-positive, and γH2AX-positive 
CPCs in the culture, compared to CPCs treated with conditioned medium from cycling-
competent CPCs or unconditioned medium (Figure 4d-f). These findings show that the 
senescent-CPCs exhibit a SASP, which can negatively impact surrounding cells, rendering 
otherwise healthy, cycling-competent CPCs to lose proliferative capacity and switch to a 
senescent phenotype. This is consistent with the spread of senescence to recipients’ cells that 
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we observed after transplanting another senescent progenitor cell type, senescent adipocyte 
progenitors (Xu et al. 2018). 
 
Elimination of senescent CPCs using senolytic drugs abrogates the SASP in vitro 
Removal of p16
Ink4a
 senescent cells can delay the acquisition of age-related pathologies in 
adipose tissue, skeletal muscle, heart, blood vessels, lung, liver, bone, and eye (Baker et al. 
2011; Xu et al. 2015; Roos et al. 2016; Farr et al. 2017; Ogrodnik et al. 2017; Schafer et al. 
2017; Xu et al. 2018, Zhu et al. 2015; Lehmann et al. 2017; Baker et al. 2016). Recent studies 
have documented the use of senolytic drugs for the selective clearance of senescent cells from 
‘aged’ tissues (Tchkonia and Kirkland, 2018). We tested the potential of 4 senolytic drugs, 
Dasatinib (D; an FDA-approved tyrosine kinase inhibitor), Quercetin (Q; a flavonoid present 
in many fruits and vegetables), Fisetin (F; also a flavonoid), and Navitoclax (N; an inhibitor 
of several BCL-2 family proteins), alone and in combination to eliminate and clear senescent-
CPCs in vitro (Supplementary Figure 9a). Measuring cell viability with crystal violet and 
number of SA-β-gal-positive CPCs, dose-response experiments on senescent- or cycling-
competent CPCs from the same subjects showed D and N to effectively clear senescent-
CPCs, whereas F and Q were less effective at clearing senescent-CPCs (Supplementary 
Figure 9b,c). However, D also decreased the viability of cycling-competent CPCs 
(Supplementary Figure 9b). A combination of D+Q, which has previously shown to yield 
effective senescent cell clearance (Roos et al. 2016; Farr et al. 2017; Ogrodnik et al. 2017; 
Schafer et al. 2017; Xu et al. 2018, Zhu et al. 2015; Lehmann et al. 2017) and which does not 
share the toxic anti-neutrophil and anti-platelet side effects of N (Kirkland et al. 2015; 
Kirkland and Tchkonia, 2017)
 
was tested, and at a dose of 0.5µM D with 20µM Q, cycling-
competent CPC viability was preserved (Figure 5a), but senescent-CPCs were cleared and 
induced to selective apoptosis (Supplementary Figure 9d).  
 
We next determined whether clearing senescent-CPCs using D+Q would abrogate the SASP 
and its paracrine impact on CPCs. Using transwell inserts, cycling-competent CPCs were 
seeded on the top chamber insert and co-cultured in the presence of senescent-CPCs seeded 
on the bottom chamber. Cultures were left for 7 days and then cycling-competent CPCs in the 
top chamber were analysed for proliferation and markers of senescence, p16
INK4A
, SA-β-gal, 
and γH2AX, and conditioned medium analysed for SASP factors. The cultures were then 
treated with D+Q for 3 days to clear the senescent-CPCs on the bottom chamber, and then 7 
days later cycling-competent CPCs in the top chamber were analysed for proliferation and the 
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markers of senescence, p16
INK4A
, SA-β-gal, and γH2AX, and conditioned medium analysed 
for SASP factors (total of 17 days; Supplementary Figure 9a). We found that cycling-
competent CPCs co-cultured in the presence of senescent-CPCs for 7 days were decreased 
(P<0.05) in number and proliferation, and had increased (P<0.05) expression of p16
INK4A
, 
SA-β-gal, and γH2AX (Figure 5b-f). Application of D+Q to co-cultures eliminated the 
senescent-CPCs (Figure 5g) and 7 days later, the cycling-competent CPCs had increased 
(P<0.05) in number (Figure 5h), proliferation (Figure 5i), and the number of p16
INK4A
 and 
SA-β-gal CPCs had decreased (P<0.05) compared to CPCs that had been in co-culture with 
senescent-CPCs for 17 days (Figure 5j,k). Co-culture of cycling-competent CPCs with 
senescent-CPCs led to increased (P<0.05) secretion of SASP factors into the medium, but the 
level of SASP factors was reduced (P<0.05) with application of D+Q (Figure 5l). These 
findings document that senescent CPCs have a SASP, and clearance of senescent CPCs using 
a combination of D+Q senolytics abrogates the SASP and its detrimental senescence-
inducing effect on healthy, cycling-competent CPCs.  
 
Elimination of senescent cells in vivo activates resident CPCs and increases number of 
small, proliferating cardiomyocytes in the aged heart 
To determine the effects of global senescent cell removal on the heart, 24-32 month INK-
ATTAC transgenic or wild-type mice were randomised to either vehicle, AP20187, or D+Q 
treatment, administered in 4 cycles for 3 consecutive days/cycle, 12 days apart. Mice were 
sacrificed 4 days after the last dose of cycle 4 (Figure 6a). Tissues in which p16
Ink4a
 
expression and/or senescent cells are decreased by D+Q in wild type mice as well as by 
AP20187 in INK-ATTAC mice include the aorta, adipose tissue, cardiac and skeletal muscle, 
lung, liver, and bone (Baker et al. 2016; Roos et al. 2016; Farr et al. 2017; Ogrodnik et al. 
2017; Schafer et al. 2017; Xu et al. 2018, Zhu et al. 2015; Lehmann et al. 2017).We showed 
p16
Ink4a
 mRNA expression was decreased (P<0.05) in the heart following D+Q or AP20187 
treatment in aged INK-ATTAC or wildtype mice (Figure 6b). 
 
Previously we have shown an improvement of heart function in old mice after D+Q treatment 
(Zhu et al. 2015). Analysis of cardiac cross-sections revealed significantly higher (P<0.05) 
CPC (Sca-1
+
/c-kit
+
/CD45
-
/CD31
-
/CD34
-
) (Vicinanza et al. 2017) numbers (Figure 6c; 
Supplementary Figure 10a) in AP20187-treated INK-ATTAC mice and D+Q-treated INK-
ATTAC or wild-type mice, compared to vehicle-treated control. Interestingly, D+Q treatment 
showed increased (P<0.05) CPC number, compared to AP20187-treatment (Figure 6c). 
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Roughly 10% of CPCs were activated and in the cell cycle (Ki67-positive) at the time of 
sacrifice, after AP20187 or D+Q treatment (Supplementary Figure 10b). Morphometric 
analysis of heart sections showed that AP20187-treated and D+Q-treated mice had increased 
number of smaller ventricular myocytes (Figure 6d), suggesting these myocytes to be 
immature and newly formed, compared to vehicle-treated mice, which exhibited only rare 
small myocytes but a greater proportion of hypertrophied myocytes (Figure 6d). We found 
an increase (P<0.05) of small, proliferating Ki67-positive myocytes (~0.25%) in old hearts 
following AP20187- or D+Q-treatment, compared to vehicle-treated control (0.03±0.03%) 
(Figure 6e,f). To corroborate these data we injected EdU 4 days and 2 hours prior to sacrifice 
of old (22m) and young (3m) AP20187-treated INK-ATTAC mice (Supplementary Figure 
10c). We found increased (P<0.05) number of small EdU-positive myocytes (0.25±0.06%; 
Figure 6g,h) in the hearts of old AP-treated mice, compared to old vehicle-treated 
(0.07±0.00%), young vehicle-treated (0.12±0.03%) and young AP-treated (0.11±0.04%) 
mice. The number of EdU-positive myocytes in the old AP-treated INK-ATTAC mice was 
the same in amount to Ki67-positive myocytes (~0.25%) in AP20187- or D+Q-treated mouse 
hearts (Figure 6f). Finally, we detected a decrease (P<0.05)  in fibrosis in the LV following 
AP20187- and D+Q-treatment, compared to vehicle-treated control (Figure 6i). In contrast to 
the treatment of aged mice, treatment of young adult (2-3 Months) INK-ATTAC or wild-type 
mice with AP20187 or D+Q, respectively, did not alter EdU-positive myocyte number 
(Figure 6h), CPC numbers or myocyte diameter (data not shown). These findings show that 
clearance of senescent cells leads to stimulation of CPCs and cardiomyocytes with increased 
DNA-synthesising activity proliferation and that this strategy is specific to the aged heart.
 
 
Discussion 
In a large sample cohort Oour study shows that CPCs isolated from the failing human heart 
develop a senescent phenotype with age exhibited by increased expression of senescence-
associated markers (p16
INK4A
, SA-β-gal), DNA damage, shortened telomere length and a 
SASP. Aged human hearts with dilated cardiomyopathy showed greater numbers of p16
INK4A 
–positive CPCs and cardiomyocytes with shorter telomeres than age-matched controls 
(Chimenti et al. 2003). Similarly, CPCs isolated from failing, aged hearts show increased 
p16
INK4A 
and inflammatory factor expression (Cesselli et al. 2011). Reliably detecting 
senescent cells in vivo is an ongoing challenge, and it is important that a combination of 
senescent cell biomarkers are used for detection as any one marker used in isolation is prone 
to false positives. Our study used a combined panel of the senescence-associated biomarkers, 
Formatted: Font: Italic
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p16
INK4A, γH2AX, telomere length, SA β-gal activity and SASP expression, to detect 
senescent CPCs. A limitation of our study is that because of low yield of CPCs isolated from 
small myocardial samples (~45,000 per gram of tissue) we were unable to evaluate the 
expression of SASP factors on freshly isolated CPCs, or test the effects of the SASP of 
freshly isolated CPCs in vitro. Our findings demonstrate that CPCs accumulate in the failing 
hearts of elderly subjects (>76 years) and are dysfunctional, showing impaired proliferation, 
clonogenicity, spherogenesis, and differentiation, compared to CPCs isolated from the hearts 
of middle-aged (32-66 years) subjects. As the adult heart possesses very low numbers (<1% 
of c-kit
pos
 cells) of cardiomyogenic CPCs (Vicinanza et al. 2017), if by 80 years of age >50% 
of resident CPCs are senescent, this presents a bleak outcome for harvesting healthy, 
functional CPCs from patients who are candidates for regenerative therapies and their 
autologous use. Moreover, strategies to activate the regenerative capacity of the aged heart 
through delivery of growth factors or cell therapy will also be sub-optimal. Therefore, the 
success of cardiac regenerative therapeutic approaches thus far tested for treating patients 
with heart failure and disease could be of limited efficacy in promoting myocardial 
regeneration because of the increased number of senescent, dysfunctional CPCs and 
cardiomyocytes
 
(Chimenti et al. 2003; Cesselli et al. 2011)
 
and the resultant presence of a 
cardiac SASP in the aged and failing heart that impairs the function of the remaining non-
senescent CPCs. These findings may also have implications regarding the use hearts from 
aged vs. younger donors for transplantation (Lau et al. 2019). 
 
The present study found that CPCs age in a stochastic non-autonomous manner and it is 
possible to clonally select from a single CPC for a cycling-competent population of CPCs 
even from diseased or aged hearts. There are individual CPCs in older individuals that have 
replicative and functional capacities resembling those of CPCs in younger subjects. A similar 
scenario was found in the case of rat fat cell progenitors (Kirkland et al. 1990). While the 
abundance of progenitors cloned from adipose tissue that had restricted capacities for 
replication and differentiation into adipocytes or that were non-replicative but viable (i.e., 
senescent) increased progressively with aging in rat fat, there remained cells that had the 
capacities for replication and adipogenic differentiation characteristic of clones derived from 
young rats. In the present study we utilised hypoxic conditions (5% CO2, 2% O2) to expand 
viable CPCs. Other interventional approaches have shown that senescence characteristics of 
human CPCs are alleviated by Pim-1 kinase resulting in rejuvenation of CPC phenotypic and 
functional properties (Mohsin et al. 2013). Together, these findings indicate that: (1) it may 
Formatted: Font: Italic
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be feasible to isolate and propagate CPCs even from older individuals that are functional, 
capable of supporting cardiac regeneration if removed from their toxic milieu, and that could 
be therapeutically relevant in treating patients, especially if they were autologously generated 
and (2) that by clearing senescent CPCs with a toxic SASP from the aged heart, there remains 
a tissue-resident population of CPCs with regenerative and reparative potential. 
 
When we purified for a homogenous SA-β-gal-positive, senescent CPC population, we 
showed that these cells had poor engraftment and survival, and were unable to contribute to 
cardiac regeneration, repair or restoration of cardiac function following transplantation into 
the infarcted myocardium. This is contrary to in vitro-selected, SA-β-gal-negative, 
proliferative cycling-competent (Ki67
pos
) CPCs, which had high survival and engraftment in 
the infarct/border zone, restored cardiac function almost to baseline and sham control values 
(LVEF 59±2% at 28 days vs. 66±2 at baseline), decreased infarct size, differentiated into 
endothelial and cardiomyocyte-like precursor cells as well as enhanced endogenous new 
BrdU
pos 
cardiomyocyte and capillaries.y formation. Although some of the transplanted CPCs 
expressed α-sarcomeric actin, these cells did not exhibit the typical cardiomyocyte phenotype 
as they were small and lacked a structured sarcomeric unit. Therefore, they could not be 
considered as new, immature myocytes which that contributed physiologically to the 
substantially improved LV function. There is now a general consensus that the favourable 
effect of cell transplantation protocols is, at least in part, mediated by ‘paracrine’ effectors 
secreted by the transplanted cells, contributing to improved myocardial contractility and 
amelioration of ventricular remodelling (decreasing fibrosis, hibernation, and stunning), 
inhibition of the inflammatory response, and increased cardiomyocyte survival, 
cardiomyogenesis and angiogenesis/neovascularisation (Broughton et al. 2018). The present 
data emphasize the importance of taking into account the hostile infarcted environment, 
which does not favour engraftment, differentiation or maturation of newly formed 
cardiomyocytes derived from injected cells. However, the presence of CPC-derived 
cardiomyocyte precursors expressing sarcomeric protein in the infarct/border zone is 
promising and further work should elucidate how to mature these cells into functionally 
competent contractile cells.   
 
Like the present study, not all experimental studies have shown physiological regeneration of 
CPC-derived cardiac muscle following administration of CPCs (Tang et al. 2016). This is 
most likely due to the heterogeneous nature of cardiac c-kit positive cells tested, with only a 
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very small fraction (1-2%) having properties of stem cells (Vicinanza et al. 2017). Bringing 
together the cardiomyogenic potential of CPCs, which can be amplified in number through in 
vitro single cell-derived clonal selection and CPC-mediated cytokine release, advocate CPCs 
as an ideal candidate for cardiac regenerative interventions.  
 
Senescent cells have emerged as bona fide drivers of aging and age-related CVD, which 
suggests strategies aimed at reducing or eliminating senescent cells could be a viable target to 
treat and prevent CVD (Childs et al. 2018). In 18 month old INK-ATTAC mice p16
INK4a
-
positive cells contribute to cardiac aging
 
and these senescent cells decreased following 
AP20187-treatment (Baker et al. 2016). Moreover, D+Q administration over 3 months 
decreased senescent cell markers (TAF+ cells) in the media layer of the aorta from aged (24 
months) and hypercholesterolemic mice, which was met with improved vasomotor function 
(Roos et al. 2016). We show for the first time that the genetic and pharmacological 
approaches used here to reduce senescent cell burden leads to increased number of CPCs and 
smaller ventricular myocytes, which were Ki67-positive and EdU-positive, suggesting these 
myocytes to be immature and newly formed (Ellison et al. 2013), compared to vehicle-treated 
mice, which exhibited very rare small myocytes but a greater proportion of hypertrophied 
myocytes. These findings are in line with those of Baker et al. (2016) who showed that AP-
treated INK-ATTAC mice had smaller ventricular cardiomyocytes.  
 
The frequency of resident cardiac stem and progenitor cells in the healthy myocardium of 
several mammalian species, including human, mouse, rat, and pig, is approximately one per 
every 1000–2000 myocytes, depending on age (Torella et al. 2007). We detected a 16- and 
23-fold increase in the number of CPCs following elimination of senescent cells by AP- or 
D+Q-treatment in the aged mouse heart, respectively. Moreover, ~10% of CPCs after 
elimination of senescent cells were activated, expressing Ki67. The number of Ki67-positive 
and EdU-positive cardiomyocytes increased 9- and 4-fold in the aged heart, respectively, 
following clearance of senescent cells by either D+Q- or AP-treatment. We show that tThe 
number of proliferating DNA-synthesising cardiomyocytes present in the young (3 month 
old) mouse heart is 0.12±0.03% of total cardiomyocytes, and the number of DNA-
synthesising proliferating cardiomyocytes present in the old (22 month old) mouse heart is 
0.07±0.00% of total cardiomyocytes. Elimination of senescent cells lead to double the 
amount of the proliferating cardiomyocytes found in a young heart, and triple the number 
found in an old heart. Therefore, the present data represent a significant and physiologically 
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relevant increase and activation of the resident CPC compartment and increased 
cardiomyocyte proliferation DNA synthetic activity following clearance of senescent cells. 
These findings are consistent with the hypothesis that clearing senescent cells can 
beneficially alter stem and progenitor cell function across multiple tissues. D+Q enhances 
function of osteoblastic progenitors, leading to new bone formation in mice with age-related 
osteoporosis, impedes function of the osteoclast progenitors that lead to bone resorption in 
these same mice (Farr et al. 2017), and enhances neurogenesis in mice with metabolically-
induced impairment of nerve cell generation (Ogrodnik et al. 2018). 
 
Previous work has shown that senescent human primary preadipocytes, human omental 
adipose tissue cells obtained from obese individuals (45.7±8.3 years), as well as human 
umbilical vein endothelial cells (HUVECs) develop a SASP with aging, which induced 
inflammation in healthy adipose tissue and preadipocytes (Xu et al. 2018; , Xu et al. 2015). 
Clearance of senescent cells using D+Q decreased the secretion of key SASP components, 
PAI-1, GM-CSF, IL-6, IL-8 and MCP-1 (Xu et al. 2018). In the present study, clearance of 
senescent human CPCs using D+Q abrogated the SASP, and the deleterious impact of the 
SASP on CPC proliferation and inducing senescence. Thus D+Q can kill human senescent 
cells, including tissue specific stem/progenitor cells, and can attenuate the secretion of 
inflammatory cytokines associated with human age-related frailty (Xu et al. 2018). Consistent 
with this, in the first human trial of senolytics, subjects with idiopathic pulmonary fibrosis 
had enhanced walking endurance, gait speed, chair rise test performance, and scores in the 
Short Physical Performance Battery 5 days after 9 doses of D+Q over 3 weeks (Justice et al. 
2018). 
 
In conclusion, the present work, albeit performed in mice models, demonstrates approaches 
that eliminate senescent cells may be useful for treating age-related cardiac deterioration and 
rejuvenating the regenerative capacity of the aged heart. However, caution should be 
exercised in interpreting mouse data considering previous cardiac regenerative strategies 
where bone marrow derived cells were injected into mouse MI models did not translate into 
equivalent outcomes in humans. Future work should address the effects of senolytic agents on 
improving cardiac function and alleviating the SASP, resulting in an improved 
microenvironment in vivo and the activity of other cell types such as fibroblasts and 
endothelial cells. Indeed, The next steps would be toshould determine whether senolytic 
approaches could be used in conjunction with cell therapy interventions to improve the 
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environment (the ‘soil’) that the cells (the ‘seeds’) are being transplanted into and therefore 
ameliorate intrinsic reparative mechanistic processes that are compromised with age (Lau et 
al. 2019). Indeed, targeting senescent cells could also impact the potency of resident 
stem/progenitor populations in other aged organs. The present findings provide new insights 
into therapies that target senescent cells to prevent an age-related loss of regenerative 
capacity. 
 
Experimental Procedures 
Expanded experimental procedures are in the supporting information. 
Myocardial samples (~200mg each) were obtained from the right atrial appendage (total 
samples, n=119) of human subjects with cardiovascular disease, aged 32-86 years. Subjects 
aged 70-86 years were included in the old group. Subjects aged 32-67 years were included in 
the middle-aged group. All subjects gave informed consent before taking part in the study 
(NREC #08/ H1306/91). Cardiac tissue was minced and enzymatically digested to release 
cardiac small cells. CPCs were purified by first depleting CD45
pos
 and CD31
pos
 cells by 
immunolabelling with anti-human CD45 and CD31 magnetic immunobeads (Miltenyi), and 
then the CD45- CD31-depleted fraction was enriched for c-kit
pos
 cells through incubation 
with anti-human CD117 immunobeads (Miltenyi). CPCs were characterised by flow 
cytometry for other CPC markers before proceeding with functional in vitro and in vivo 
assays. All animal surgical experiments were conducted in accordance with the regulations of 
the Home Office and stipulated under the Animals (Scientific Procedures) Act 1986.  
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Figure. 1. Over half of CPCs in the aged human heart are senescent (a) Representative 
immunofluorescence images and quantification of c-kit
pos
 p16
INK4Apos 
CPCs, (n=35 donors2), 
(b) c-kit
pos
 SA-β-galpos CPCs (*P=0.0014; n=2-4), (c) c-kitpos γ-H2AXpos p16INK4A-expressing 
CPCs (*P=0.0264; n=5 donors). (d) Q-FISH telomere length of single c-kit
pos
 CPCs (n=100 
cells per group, 20 cells per donor). Representative immunofluorescence images of telomere 
staining, L5178Y-S (10 Kb) and L5178Y-R (79 Kb) are mouse cell lines with known 
telomere length. Frequency distribution histogram of CPC telomere length (n=5 
donors/group). Nuclei stained in blue by DAPI. All data are Mean ± SEM.  
Figure. 2. CPCs isolated from aged hearts exhibit diminished proliferation, 
clonogenicity, and cardiomyocyte differentiation potential (a) Quantification of CPC 
proliferation (*P=0.0266; n=3-4 donors), (b) single CPC-derived clonal efficiency 
(*P=0.0008, n=4-5 donors), (c) CPC spherogenesis number (*P=0.0051) and (d) size 
(*P=0.01), (n=2-3 donors). (e) Representative immunofluorescence images of 
undifferentiated and differentiated CPCs from old and middle-aged donors. Nuclei stained in 
blue by DAPI. (f) Quantification of Nkx2.5
pos
 (*P=0.0295; n=3 donors2), and (g) α-
sarcomeric actin expression (*P=0.023; n=2-3 donors). All data are Mean ± SEM.  
Figure. 3. Aged-senescent CPCs show decreased reparative potential (a) In vivo MI 
experimental design. (b) Representative confocal images of PKH26
pos 
CPCs engrafted in the 
myocardium 4 days post-MI. (c) Quantification  and representative confocal images of 
engraftment of PKH26
pos 
cells 28 days post-MI (*P=0.015 vs. c-kit
neg 
cells, n=4-5 mice). (d) 
Echocardiography measurements of LV ejection fraction (EF), fractional shortening (FS), left 
ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter 
(LVESD) at baseline (BL) before MI, 7 and 28 days after MI and cell injection (*P<0.05 vs. 
Sham, †P<0.05 vs. Cycling-CPCs, ΔP<0.05 vs. dox-induced Sen-CPCs, n=5-7 mice). (e) 
Representative micrographs and quantification of average LV fibrosis (*P<0.05 vs. Sham; 
†P=0.0112 vs. Cycling-CPCs; n=5-6 mice). (f) Representative confocal images of PKH26 co-
expression with α-sarcomeric actinin and vWF (arrowheads) 28 days post-MI. (g) 
Quantification and representative confocal images of BrdU
pos
/α-sarcomeric actininpos 
cardiomyocytes and BrdU
pos
/vWF
pos
 capillaries (*P<0.05 vs. all; n=5-7 mice). Nuclei stained 
in blue by DAPI. All data are Mean ± SEM.  
Figure. 4. Aged-senescent CPCs have a SASP (a) Transcript SASP factor expression of 
dox-induced Sen-CPCs relative to Cycling-CPCs (control). (b) SASP factor protein levels 
quantified by Luminex of unconditioned media (UM), Cycling- CPC (CM) and dox-induced 
Sen-CPC (Sen CM) conditioned media (*P<0.05 vs. UM and CM). Conditioned media 
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applied to cycling-competent CPCs and the following analyses performed; (c) Quantification 
and representative staining of CPC proliferation (*P<0.001; n=5 replicates), (d) p16
INK4A-pos 
CPCs (*P<0.0001; n=5 replicates), (e) SA-β-galpos CPCs (*P<0.0001; n=5 replicates), (f) 
γH2AXpos CPCs (*P<0.001; n=5 replicates). All data are Mean ± SEM.  
Figure. 5. Senolytic clearance abrogates the SASP (a) Viability (Crystal violet) and SA-β-
gal quantification of dox-induced Sen-CPCs and Cycling-CPCs exposed to various 
concentrations of D+Q for 3 days. (b-f) Quantification of 7 days of co-culture of Cycling-
CPCs with dox-induced Sen-CPCs for (b) viability (*P=0.0068); (c) proliferation 
(*P=0.0056); (d) p16
INK4A 
(*P=0.0025); (e) SA-β-gal (*P=0.0025); (f) γH2AX (*P=0.0002). 
CTRL is Cycling- CPCs alone. (n=5 replicates). Data are Mean ± SEM. (g) Representative 
SA-β-gal staining after clearance of dox-induced Sen-CPCs from co-culture by D+Q 
treatment. (h-k) Quantification of 17 days of co-culture of Cycling-CPCs with dox-induced 
Sen-CPCs or co-culture with D+Q treatment for (h) viability (*P<0.0001 vs. CTRL 17d; 
†P=0.0001 vs. co-culture 17d); (i) proliferation (*P<0.0001 vs. CTRL 17d; †P<0.0001 vs. co-
culture 17d); (j) p16
INK4A 
(*P<0.0001 vs. CTRL 17d; †P<0.0001 vs. co-culture 17d) and (k) 
SA-β-gal (*P<0.0001 vs. CTRL 17d; †P<0.0001 vs. co-culture 17d). CTRL is Cycling-CPCs 
alone. (n=5 replicates). (l) SASP factor protein levels quantified by Luminex from each 
treatment condition (*P<0.0001 vs. CTRL; †P<0.01 vs. co-culture 7d and 17d). (n=2 
replicates). All data are Mean ± SEM.  
Figure. 6. Clearance of senescent cells stimulates new cardiomyocyte formation in in the 
aged heart (a) In vivo senescent cell clearance experimental design.  (b) Total cardiac 
p16
Ink4a
 gene expression following clearance (*P<0.01 vs. Vehicle; n=5 mice). (c) 
Quantification of CPCs following clearance, (*P<0.0001 vs. Vehicle; †P=0.0453 vs. AP; 
n=10-11 mice). (d) Frequency distribution histogram of cardiomyocyte diameter, (n=6 mice). 
(e) A Ki67
pos
/α-sarcomeric actinpos cardiomyocyte (arrowhead) in the LV of a 32 month 
D+Q-treated mouse. (f) Quantification of Ki67
pos 
cardiomyocytes, (*P<0.0001 vs. Vehicle; 
n=10 mice). (g) An EdU
pos
/α-sarcomeric actinpos cardiomyocyte in the LV of a 22 month 
INK-ATTAC AP-treated mouse. Nuclei are stained by DAPI in blue. (h) Quantification of 
EdU
pos 
cardiomyocytes (*P<0.0001 vs. Old+Vehicle; †P<0.0001 vs. Young+AP; n=5 mice). 
(i) Quantification of LV fibrosis (*P<0.05 vs. Vehicle; n=3 mice). All data are Mean ± SD.  
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